Vor Biopharma Inc.
VOR
$7.53
-$0.15-1.95%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 14.42M | 2.40M | 6.59M | 5.96M | 6.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.14M | 243.55M | 33.29M | 31.31M | 28.51M |
| Operating Income | -29.14M | -243.55M | -33.29M | -31.31M | -28.51M |
| Income Before Tax | -812.68M | -1.57B | -32.49M | -30.71M | -27.56M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -812.68M | -1.57B | -32.49M | -30.71M | -27.56M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -812.68M | -1.57B | -32.49M | -30.71M | -27.56M |
| EBIT | -29.14M | -243.55M | -33.29M | -31.31M | -28.51M |
| EBITDA | -29.13M | -241.51M | -32.47M | -30.45M | -27.66M |
| EPS Basic | -121.63 | -251.24 | -5.21 | -8.77 | -8.05 |
| Normalized Basic EPS | -76.11 | -153.96 | -3.25 | -5.48 | -5.03 |
| EPS Diluted | -121.63 | -251.24 | -5.21 | -8.77 | -8.05 |
| Normalized Diluted EPS | -76.11 | -153.96 | -3.25 | -5.48 | -5.03 |
| Average Basic Shares Outstanding | 6.68M | 6.26M | 6.24M | 3.50M | 3.42M |
| Average Diluted Shares Outstanding | 6.68M | 6.26M | 6.24M | 3.50M | 3.42M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |